1,101
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluation

Aripiprazole for treating irritability associated with autism spectrum disorders

, & ORCID Icon
Pages 1421-1427 | Received 19 Feb 2019, Accepted 30 May 2019, Published online: 10 Jun 2019
 

ABSTRACT

Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a reported prevalence of 1 in 59 people. Its core features are persistent deficits in social communication and restricted, repetitive patterns of behavior or interests. Individuals with ASD have a high incidence of secondary problems with mood lability, tantrums, self-injurious behavior and aggressiveness toward others. Collectively, these behaviors are often referred to as irritability. Many medications have been used to treat irritability in autism, with aripiprazole one of only two medications approved in the USA for this purpose.

Areas covered: Herein, the authors review the evidence supporting the use of aripiprazole for treating irritability in autism, including the pivotal trials leading to regulatory approval and long-term studies conducted post-approval. They utilized PubMed, searching all English language publications since 2000, using the terms aripiprazole, autism, autism spectrum disorder, pervasive developmental disorder, Asperger’s disorder, and irritability, and focused on clinical trials and review articles.

Expert opinion: Multiple studies have shown the clear benefit of aripiprazole in the treatment of irritability in autism disorders compared to placebo. Often underemphasized are the metabolic effects, the proper monitoring for these effects, and the need for periodic reassessment to determine if ongoing treatment is needed.

Article highlights

  • Autism spectrum disorder is a neurobehavioral disorder manifested by problems with social communication, and with restricted interests and/or repetitive behaviors.

  • At this time there are no medical treatments for the core symptoms of autism. As a result, pharmacotherapy is directed toward secondary symptoms or conditions such as anxiety, hyperactivity and irritability.

  • Irritability, comprised of severe tantrums, mood swings and aggressive behavior, is identified by family members as the most problematic behavior in people with autism.

  • Evidence exists supporting effectiveness of two atypical antipsychotic medications in the treatment of irritability in autism.

  • Aripiprazole can be a useful treatment for irritability in autism, but careful monitoring for neurologic and metabolic side effects must be conducted.

Declaration of interest

DL Coury has served on advisory boards for Cognoa, BioROSA and Quadrant Biosciences. He has also received grant support from Stemina Biosciences, Neurim, and Stalicla. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Box 1. Drug summary box

Additional information

Funding

This manuscript has not been funded.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.